Join our community of smart investors

Croda’s earnings drop in line with expectations

Post-pandemic destocking has had a material impact on earnings at the specialty chemicals company
July 25, 2023
  • Dividend maintained in spite of challenges
  • Pharma business to drive growth

Investors rarely respond well to an objectively lacklustre company update. Croda International’s (CRDA) half-year results – which showed substantial declines in both revenue and pre-tax profit – proved to be something of an exception. The company’s shares rose by nearly 5 per cent on the morning the figures were released. 

This is subscriber only content
Start your trial to keep reading
PRINT AND DIGITAL trial

Get 12 weeks for £12
  • Essential access to the website and app
  • Magazine delivered every week
  • Investment ideas, tools and analysis
Have an account? Sign in